or Try an Advanced Search...

    Technical Analysis for VRNA - Verona Pharma plc

    Grade Last Price % Change Price Change
    C 15.51 7.26% 1.05
    VRNA closed up 7.26 percent on Monday, July 1, 2024, on 1.93 times normal volume.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Up
    Historical VRNA trend table...
    Date Alert Name Type % Chg
    20 DMA Support Bullish 0.00%
    Bullish Engulfing Bullish 0.00%
    Wide Bands Range Expansion 0.00%
    50 DMA Support Bullish 7.26%
    Wide Bands Range Expansion 7.26%
    200 DMA Resistance Bearish 0.45%
    Pocket Pivot Bullish Swing Setup 0.45%
    Volume Surge Other 0.45%
    Outside Day Range Expansion 0.45%
    Wide Bands Range Expansion 0.45%
    Older End-of-Day Signals for VRNA ...

       Recent Intraday Alerts

    Alert Time
    10 DMA Resistance about 4 hours ago
    Up 5% about 4 hours ago
    Possible Inside Day about 6 hours ago
    Up 3% about 6 hours ago
    Up 2% about 8 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    VRNA Chart by TradingView
    Basic chart:

    Profile

    Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company's lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma. Verona Pharma plc is based in London, the United Kingdom.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Asthma Respiratory Therapy Chronic Obstructive Pulmonary Disease Respiratory Diseases Cystic Fibrosis Phosphodiesterase Lung Disorders

    Is VRNA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 30 Verona Pharma Is Launching Ohtuvayre, Although There Will Be Competition
    Jun 27 Verona scores FDA approval for Ohtuvayre as COPD maintenance therapy
    Jun 27 First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product
    Jun 27 FDA go-ahead for Verona Ohtuvayre transforms US COPD exacerbator market
    Jun 26 Verona wins FDA approval of ensifentrine for COPD; stock surges 20%
    Jun 26 Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)
    Jun 24 5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
    Jun 20 Verona Pharma: Next Week's PDUFA Date Ought To Provide An Upside Catalyst
    Jun 13 Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
    May 29 Verona prepares for anticipated US launch of ensifentrine for COPD in Q3 2024
    See more VRNA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 23.07
    52 Week Low 11.395
    Average Volume 1,095,997
    200-Day Moving Average 15.62
    50-Day Moving Average 14.15
    20-Day Moving Average 14.22
    10-Day Moving Average 15.27
    Average True Range 1.08
    RSI (14) 56.90
    ADX 37.05
    +DI 26.80
    -DI 13.64
    Chandelier Exit (Long, 3 ATRs) 13.77
    Chandelier Exit (Short, 3 ATRs) 14.63
    Upper Bollinger Bands 17.19
    Lower Bollinger Band 11.26
    Percent B (%b) 0.72
    BandWidth 41.70
    MACD Line 0.45
    MACD Signal Line 0.35
    MACD Histogram 0.0966
    Fundamentals Value
    Market Cap 1.24 Billion
    Num Shares 79.9 Million
    EPS -0.56
    Price-to-Earnings (P/E) Ratio -27.70
    Price-to-Sales 2981.17
    Price-to-Book 5.16
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 17.61
    Resistance 3 (R3) 17.39 16.47 17.26
    Resistance 2 (R2) 16.47 15.93 16.58 17.14
    Resistance 1 (R1) 15.99 15.60 16.23 16.21 17.03
    Pivot Point 15.07 15.07 15.19 15.18 15.07
    Support 1 (S1) 14.59 14.54 14.83 14.81 13.99
    Support 2 (S2) 13.67 14.21 13.78 13.88
    Support 3 (S3) 13.19 13.67 13.76
    Support 4 (S4) 13.41